Publicaciones en las que colabora con Susana Ravassa Albéniz (49)

2024

  1. Circulating biomarkers of myocardial remodelling: current developments and clinical applications

    Heart, Vol. 110, Núm. 19, pp. 1157-1163

  2. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management

    Hypertension, Vol. 81, Núm. 2, pp. 218-228

2023

  1. A Comparison of Methodologies for Pulmonary Veins Segmentation in High Definition Voltage Maps of Patients with Atrial Fibrillation

    Computing in Cardiology

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  3. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

  4. Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms

    Life, Vol. 12, Núm. 6

  5. Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease

    European Journal of Vascular and Endovascular Surgery, Vol. 63, Núm. 4, pp. 648-656

  6. Using High-Resolution Voltage Maps to Predict 'redo' in the Treatment of Atrial Fibrillation (AF)

    Computing in Cardiology

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports

  2. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

  3. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?

    Journal of Clinical Medicine, Vol. 9, Núm. 2

  4. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

  3. MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure

    Scientific Reports, Vol. 7

  4. The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes

    Medical Clinics of North America, Vol. 101, Núm. 1, pp. 43-52

  5. Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥60 Years With Heart Failure and Reduced Ejection Fraction

    American Journal of Cardiology, Vol. 119, Núm. 12, pp. 2042-2048

2016

  1. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: Potential role of altered collagen metabolism

    Journal of Hypertension, Vol. 34, Núm. 1, pp. 130-138